Physician

Ayman Alibrahim, M.D.

According to 2025 Medicare claims, Ayman Alibrahim, M.D. (NPI: 1063469104) practices allergy/immunology in the Homosassa Springs, FL market, with the plurality of this provider's patient population coming from Citrus, FL. This provider's primary affiliated billing organization is ADVANCED ALLERGY ASTHMA&IMMUNOLOGY (NPI: 1811041064; TIN: 205423393) and primary practice location at 34461-7552.

Alibrahim's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 563 traditional Medicare patients, billed 24,116 HCPCS/CPT codes, and received $219,767 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 3,826 prescription claims across 678 beneficiaries totaling $1,209,813 in drug costs, led by Dupixent Syringe (Dupilumab). DME data shows 140 claims. Open Payments data shows 93 records totaling $1,833. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $251,330 to $1,209,813. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $7,571 and ending at $6,811.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	359	19,828	$205,927
2016	402	21,075	$216,462
2017	391	22,860	$225,708
2018	432	23,623	$218,585
2019	472	24,472	$224,070
2020	453	24,179	$223,117
2021	504	23,548	$229,526
2022	539	24,035	$227,588
2023	549	24,454	$227,023
2024	563	24,116	$219,767

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	318	2,329	$251,330
2016	367	2,390	$282,751
2017	390	2,762	$342,922
2018	458	2,989	$480,092
2019	506	3,128	$609,996
2020	517	3,375	$869,602
2021	549	3,476	$971,309
2022	605	3,424	$1,069,613
2023	646	3,502	$1,074,931
2024	678	3,826	$1,209,813

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	79	377	$37,067
2016	39	398	$102,669
2017	12	287	$71,170
2018	N/R	211	$70,636
2019	N/R	194	$67,925
2020	N/R	252	$158,019
2021	N/R	90	$20,876
2022	N/R	108	$84,949
2023	N/R	135	$138,531
2024	N/R	140	$305,271

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	240	351	$86
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	322	411	$64
94010	Test to measure expiratory airflow and volume	229	376	$19
95012	Test to measure the level of nitric oxide gas	265	414	$13
95004	Test for allergy using allergenic extract	184	13,574	$3

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Dupixent Syringe	Dupilumab	52	1,540	$208,496
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	164	9,450	$192,469
Breo Ellipta	Fluticasone/Vilanterol	138	10,080	$129,465
Gamunex-C	Immune Globul G/Gly/Iga Avg 46	15	426	$93,662
Nucala	Mepolizumab	22	616	$80,802

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1575	Injection, immune globulin/hyaluronidase, (hyqvia), 100 mg immuneglobulin	N	N/R	19	$167,109
J1555	Injection, immune globulin (cuvitru), 100 mg	N	N/R	11	$84,468
J1559	Injection, immune globulin (hizentra), 100 mg	N	N/R	12	$49,109
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	37	$2,619
A4221	Supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separately)	N	N/R	30	$1,692

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	93	$1,833	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Ayman Alibrahim, M.D.?

Tedicare shows public-source Medicare data for Ayman Alibrahim, M.D. (NPI 1063469104), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ayman Alibrahim, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Ayman Alibrahim, M.D.?

Ayman Alibrahim, M.D. is linked to ADVANCED ALLERGY ASTHMA&IMMUNOLOGY (billing NPI 1811041064) in the available physician profile data.

Does Ayman Alibrahim, M.D. have Open Payments data?

Ayman Alibrahim, M.D. has 93 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.